SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
MicroDose Therapeutx (formerly MicroDose Technologies Inc) Begins Phase 1 Trial of MDT-637 for Treatment of Respiratory Syncytial Virus